Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

100+ results found in London, UK

Sort by:
Showing 31 - 40 of 100+ results
Oncology
21 years of experience
Medical Oncology

I am a Medical Oncology Consultant for the Gastrointestinal Oncology Service at University College London Hospitals NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Insitute. I treat oesophageal, stomach, small bowel, colorectal and hepatobiliary cancers, as well as cancers of unknown primary. I am the UCLH Clinical Lead for the Cancer of Unknown Primary (CUP) Service and the Acute Oncology Service.


My research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, with focus on clinical trials and translational research of these cancers. I am Chief Investigator or Principal Investigator for a number of  GI or CUP immuno-oncology Phase 2 and 3 trials, including KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, KEYNOTE 975,  VESTIGE, POLEM and CUPISCO.


I am Chair of the NCRI MUO-CUP Workstream as part of the Living With and Beyond Cancer CSG, and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. I am the Principal Investigator of the UCL-UCLH GI + CUP Cancer Translational Research Biobank and a collaborator with the GI Oncology and CUP subgroups at the UCL Cancer Institute and Francis Crick Institute. I am a member of ASCO, ESMO and the Association of Cancer Physicans (UK).


I strongly believe in clinicians being educators and enjoy teaching oncology to UCL medical students, oncology and non-oncology junior trainees. I also give talks nationally and abroad at conferences and other hospitals to share best practice and future perspectives in the fields of GI oncology research, CUP, immunotherapy and novel trial designs.


To make an appointment or enquiry please contact my secretary Alanna Sarwar on asarwar@theloc.com or +44207 317 2659.


Diseases, Medical Tests and Treatments
  • Gastrointestinal Oncology - oesophageal, stomach, hepatobiliary and bowel cancers
  • Cancer of Unknown Primary
  • Acute Oncology
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Clinical Trials
  • Immunotherapy
  • Gastrointestinal Oncology Research 
  • Cancer of Unknown Primary Research 
  • Molecular Profiling with solid and liquid biopsies
  • Biomarker Driven Clinical Trial Design and Implementation
Read more
Oncology
25 years of experience
Clinical Oncology

George Mikhaeel is a Professor of Radiation Oncology at King’s College London and Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Foundation Trust since 2001. He specialises in the treatment of lymphoma with both chemotherapy and radiotherapy and has extensive experience in advanced radiotherapy techniques for haematological malignancies.

Professor Mikhaeel’s research has resulted in new ways of treating lymphoma patients with radiotherapy, harnessing the benefits of advances in radiotherapy technology and advances in imaging. An example of new treatments is combining an innovative arc technique and deep inspiration breath-hold (DIBH) with image-guided delivery of treatment to improve the accuracy of targeting radiation and reduce dose to healthy tissues.

His clinical practice is focused only on haematological malignancies which are less common and require a high level of specialisation and substantial clinical experience, having practised in this field for more 20 years. Professor Mikhaeel has lectured in more than 15 countries and has numerous publications in the field including four influential international guidelines.

He is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering and executive committees. Professor Mikhaeel also chairs the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee and a reviewer for the European Society of Radiation Oncology (ESTRO). Nationally, he is the chair of the UK Lymphoma Radiotherapy Group (UK-LRG) steering committee.


Diseases, Medical Tests and Treatments


  • Radiotherapy
  • Chemotherapy


  • Haematological malignancies
Read more
Oncology
25 years of experience
Medical Oncology

Dr Rebecca Kristeleit specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has a special interest in novel therapies for gynaecological cancer and has led or been involved in a number of successful new drug applications such as rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a number of Phase I-III clinical studies including the novel use of PARP inhibitors for gynaecological malignancies.

Dr Kristeleit first qualified in 1995 from the University of Manchester after initially completing a bachelor’s degree in medical science at the University of St Andrews. She then received an ERASMUS Scholarship which allowed her to study in Switzerland before finishing her elective at Massachusetts General Hospital, Harvard University. Following this, she went on to train in medical oncology at the Royal Marsden Hospital before embarking on a CRUK-funded clinical research fellowship during which she completed a PhD on the clinical pharmacology of HDAC inhibitors at the Institute of Cancer Research.  She was also awarded a senior fellowship at the Royal Marsden Hospital's Drug Development Unit where she gained experience in early phase clinical trials. She was later appointed a clinical senior lecturer and subsequently an associate professor at UCL.

Dr Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and has been elected to the ESMO Faculty from 2021 to 2025. She has a number of publications to her name and is often asked to speak at national and international conferences as well as advise pharmaceutical companies on their gynaecological cancer drug development.

Dr Kristeleit has previously served as Chair of the BGCS Scientific Committee, the UK Oncology Forum Gynaecology Track, and the ASCO Gynaecological Cancer Scientific Committee.

Read more
Oncology
31 years of experience
Clinical Oncology

Lucy Brazil is a Consultant Oncologist who has been with Guy’s and St Thomas’ and King’s College Hospitals since 2005. In 2007, she was awarded an MD for research into breast cancer genetics at the Institute of Cancer Research and Breakthrough Breast Cancer.

Dr Brazil trained in oncology at the Royal Marsden Hospital and Guy’s and St Thomas’ Hospitals. Her specialist interests include neuro-oncology particularly high grade glioblastoma multiforme and low grade glioma including oligodendroglioma and spinal tumours and breast cancer including management of brain metastases. Dr Brazil has expertise in radiotherapy both standard conformal and stereotactic techniques and including Cyberknife, Rapid-Arc and IMRT. She also oversees chemotherapy and endocrine treatments.

Dr Brazil is a member of the NCI National Cancer Institute Brain Tumour Clinical Studies Group and the EORTC European Organisation of Research and Treatment of Cancer Brain Tumour Group. She is chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for grade 3 gliomas, chairman of the brain-tumour palliative care sub-group and neuro-oncology research lead at Guy's and St Thomas' in addition to being systemic chemotherapy neuro-oncology lead at the hospital.

 


Diseases, Medical Tests and Treatments
  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Palliative Care
  • Brain Cancer
  • Breast Cancer
  • Neuro-oncology
Read more
Oncology
28 years of experience
Clinical Oncology

Dr Vinod Mullassery is a London-based consultant clinical oncologist who specialises in urological and breast cancer management at Guy's and St Thomas' NHS Foundation Trust. He treats patients with solid tumours and uses radiotherapy, chemotherapy, hormones, and biological therapies. Dr Mullassery is the current brachytherapy lead at the hospital and also implemented the image-guided interstitial brachytherapy programme for cervical cancer.

Dr Mullassery gained his MD in 1999 before training in oncology at the University College Hospital, Great Ormond Street Hospital, and the Mount Vernon Cancer Centre, where he later undertook a post-CCT fellowship in radiotherapy techniques. In 2013, he was awarded the American Brachytherapy Society HDR Scholarship Award after spending time training at the University of California. Dr Mullassery remains involved in teaching and has tutored both undergraduate and postgraduate students. He is also involved in research and his current topics of interest are high dose rate brachytherapy and cancer imaging.

Read more
Oncology
34 years of experience

Dr Paula Wells oncology training was undertaken at St. Bartholomew's, UCLH, and Mount Vernon Hospitals; following her Fellowship, she undertook a postgraduate research degree at Imperial College School of Medicine, Hammersmith Hospital. There she investigated the potential for Positron Emission Tomography (PET) to demonstrate the biological effects of chemotherapy in tissue for which she received a number of awards. She has published a number of papers in this area and was awarded a Ph.D. for her work. Subsequently, she completed her post-doctoral training at the Royal Marsden Hospital, principally with the Academic Urology Unit.

Dr Wells specializes in the management of patients with genitourinary (bladder and prostate) and thoracic (lung and mesothelioma) malignancies and has expertise in all non-surgical treatments including chemotherapy, immunotherapy, biological and targeted therapies. She utilises state-of-the-art radiotherapy techniques including image-guided (IGRT), intensity-modulated radiotherapy (IMRT), 4D CT, and Stereotactic Radiotherapy (SABR and SRS) using both Cyberknife and Linear accelerator platforms. In addition, she has extensive experience of low dose rate brachytherapy (LDR) in the management of prostate cancer.

Since taking up her present NHS post she has been extensively involved with the development of the genitourinary and thoracic cancer services for the North East London Cancer Network.

Dr Wells has an active trial portfolio of UK clinical trials and is the principal investigator for a number of pivotal radiotherapy studies. From these activities, she took a clinical lead in the development of IMRT for prostate cancer, chemo-radiation in bladder and lung cancer and Stereotactic Radiotherapy (SABR) at Barts Health. Her research interest in Positron Emission Tomography continues to develop with an emphasis on investigating the direct effects of radiotherapy on tissue and the integration of novel therapies with radiation. She is currently Clinical Governance and Audit Lead for Barts Cancer Centre and Chairs the Stereotactic Body MDT.

 


Diseases, Medical Tests and Treatments

  • Urological (bladder, prostate)
  • Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)
  • Urological (bladder, prostate)
  • Lung (including Mesothelioma) cancers (chemotherapy and radiotherapy)
Read more
Oncology
46 years of experience
Clinical Oncology

Dr Ronald Beaney did his undergraduate training in Scotland followed by posts abroad and in the UK. His oncology training was at the Hammersmith Hospital in London where his MD thesis was on the role of positron emission tomography in oncology. He has been a Consultant Clinical Oncologist attached to Guy's and St Thomas and Kings College Hospitals in London. He has produced more than 100 publications on a range of oncological topics.

Dr Beaney's major clinical interests lie in tumours of the brain (gliomas) and pelvis (prostate and gynaecological tumours). He is a member of several UK, European and American Cancer Societies and examiner for the Royal College of Radiologists.


Diseases, Medical Tests and Treatments

Cyberknife

Gammaknife

  • Clinical oncology 
  • Gynae
  • Prostate
  • Bladder
  • Central nervous system tumours
  • Testicular Cancer
  • Renal Cancer
  • Ovarian Cancer
  • Neuroendocrine Tumours (NETs)
Read more
Oncology
24 years of experience

Dr Paul Nathan is a well-respected Consultant Oncologist with HCA Healthcare at The Harley Street Clinic and The Wellington Hospital. additionally, he holds an NHS post at East and North Herts Foundation Trust. His clinical interests include cancers of the kidneys, skin and urological tract and melanomas.

He began his career in immunology, in which he received a PhD. Following this, he returned to university at Cambridge where he was awarded his medical degree. During his studies, he was awarded the Fulbright Scholarship where he carried out a research fellowship at the Pittsburgh Cancer Institute in the USA. He remains heavily involved in research and is the lead investigator on many clinical trials, particularly in the field of immunotherapy and other targeted therapies. Throughout his career, he has published numerous journals sand contributed to medical textbooks. He is the Chair of the UK Uveal Melanoma Guidelines group and the Lead for Uveal Melanoma at the UK International Rare Cancer Initiative.

 


Diseases, Medical Tests and Treatments

  • Immunotherapy
  • Chemotherapy
  • Urological Cancer
  • Kidney Cancer
  • Renal Cancer
  • Skin Cancer
  • Melanoma
Read more
Oncology
33 years of experience
Medical Oncology

Dr Jonathan Shamash is a Consultant Oncologist and is the Lead in Acute Oncology at St Bartholomew’s Hospital and has a further NHS base at Queen’s Hospital, Romford. Dr Shamash also sees patients privately, including at Leaders in Oncology Care. He graduated from the University of Edinburgh in 1987 and then undertook post graduate training in London, gaining an MD in in-vitro modelling of lymphoma.

Dr Shamash sub-specialises in genito-urinary cancers and thoracic malignancies. He has a special interest in managing complex oncology problems and delivering intensive treatments, including high dose Interleukin-2 and high does chemotherapy in testicular cancer. . Dr Shamash also chairs the supra-regional germ cell tumour multidisciplinary meeting and is a member of the NCRI testis clinical studies group. He leads various clinical studies in the management of testicular and prostate cancer and has published widely.

Read more
Oncology
39 years of experience
Medical Oncology

Prof Siow Ming Lee is Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital (UCLH). He is an internationally recognised authority on lung cancer treatment and research.

He has led several National Cancer Research Institute (NCRI) lung cancer trials over the past three decades in UK, which have changed clinical practice and improved treatment outcomes for lung cancer patients.

His research team established the use of gemcitabine/carboplatin chemotherapy to treat lung cancer and this treatment remains the standard chemotherapy combination to treat squamous lung cancer. His innovative trials with thalidomide as a cancer weapon and the smart drug erlotinib to treat poor performance lung cancer patients received worldwide publicity including being featured on BBC Ten O’Clock News at launch. His ET trial was the first prospective biomarker chemotherapy trial with ERCC1 to select lung cancer patients for doublet chemotherapy and demonstrated that platinum combination is superior to non-platinum chemotherapy. His latest trials examine the role of atezolizumab immunotherapy to treat poor performance non-small cell lung cancer patients (IPSOS) and hydroxychloroquine to treat small cell lung cancer (Study 15). His team was also part of the international FLAURA and KEYNOTE-189 Investigators that established osimertinib and chemotherapy-pembrolizumab combination as standard first-line therapy to treat EGFR mutant and wild-type lung cancer respectively. His trials have been recognised at major international conferences with many invited Presidential, Plenary and Oral Presentations at World Lung Cancer Conference, ASCO and ESMO and resulted in several 1st or senior author publications in high impact journals. His practice-changing trials and 4* high impact research publications were used for the REF 2014 exercise which ranked UCL top for research in UK.

Professor Lee is the Clinical Lead for the UCLH Thoracic Medical Oncology Unit and chairs the London Lung Cancer Group, which has an international research reputation. He previously was chairperson for the NCRI Lung Cancer Advanced Disease Subgroup, NCRI Brain New-agents Clinical Subgroup and committee member of CTACC, NCRI Lung, NCRI Brain and NCRI Lymphoma Groups.


Diseases, Medical Tests and Treatments


  • Targeted therapies and immunotherapy for lung cancer 
  • Non-small cell lung cancer
  • Small lung cell cancer 
  • Malignant mesothelioma
  • Thymic carcinoma 
  • HIV-related cancers
Read more